Biologic basis for combining drugs with radiation

Seminars in Radiation Oncology

Volumn 16, Issue 1, 2006, Pages 2-9

  Wilson, George D ^a   Bentzen, Søren M ^b   Harari, Paul M ^b,c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXYADENOSINE 5' TRIPHOSPHATE; 5 FLUOROURIDINE DIPHOSPHATE; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLOXURIDINE PHOSPHATE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FLUOROURIDINE PHOSPHATE; FLUOROURIDINE TRIPHOSPHATE; GEFITINIB; GEMCITABINE; OXALIPLATIN; RADIOSENSITIZING AGENT; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CELL CYCLE; CELL CYCLE S PHASE; CLINICAL TRIAL; CYTOTOXICITY; DNA DAMAGE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG TARGETING; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; MISMATCH REPAIR; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; REVIEW; TARGET CELL DESTRUCTION;

EID: 29244465506     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2005.08.001     Document Type: Article

References (78)

1. J. Bernier, E.J. Hall, A. Giaccia Radiation oncology A century of achievements Nat Rev Cancer 4 2004 737 747
2. E.M. Bengtson, J.R. Rigas A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer Why we should look beyond platinum Semin Oncol 26 1999 1 6
3. G.G. Steel Terminology in the description of drug-radiation interactions Int J Radiat Oncol Biol Phys 5 1979 1145 1150
4. G.G. Steel, M.J. Peckham Exploitable mechanisms in combined radiotherapy-chemotherapy the concept of additivity Int J Radiat Oncol Biol Phys 5 1979 85 91
5. B. Rosenberg, L. VanCamp, J.E. Trosko Platinum compounds a new class of potent antitumour agents Nature 222 1969 385 386
6. A. Eastman, M.A. Barry Interaction of trans-diamminedichloroplatinum(II) with DNA Formation of monofunctional adducts and their reaction with glutathione Biochemistry 26 1987 3303 3307
7. J.C. Jones, W.P. Zhen, E. Reed Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells J Biol Chem 266 1991 7101 7107
8. A.M. Fichtinger-Schepman, R.A. Baan, A. Luiten-Schuite Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding Chem Biol Interact 55 1985 275 288
9. A.C. Plooy, M. van Dijk, F. Berends Formation and repair of DNA interstrand cross-links in relation to cytotoxicity and unscheduled DNA synthesis induced in control and mutant human cells treated with cis-diamminedichloroplatinum(II) Cancer Res 45 1985 4178 4184
10. Z.H. Siddik Cisplatin Mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
11. P. Jordan, M. Carmo-Fonseca Molecular mechanisms involved in cisplatin cytotoxicity Cell Mol Life Sci 57 2000 1229 1235
12. H. Zhao, H. Piwnica-Worms ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1 Mol Cell Biol 21 2001 4129 4139
13. G. Damia, L. Filiberti, F. Vikhanskaya Cisplatinum and taxol induce different patterns of p53 phosphorylation Neoplasia 3 2001 10 16
14. J. Agner, J. Falck, J. Lukas Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway Exp Cell Res 302 2005 162 169
15. G.D. Wilson Radiation and the cell cycle, revisited Cancer Metastasis Rev 23 2004 209 225
16. E. Appella, C.W. Anderson Post-translational modifications and activation of p53 by genotoxic stresses Eur J Biochem 268 2001 2764 2772
17. J.H. Losa, C. Parada Cobo, J.G. Viniegra Role of the p38 MAPK pathway in cisplatin-based therapy Oncogene 22 2003 3998 4006
18. S. Schweyer, A. Soruri, O. Meschter Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation Br J Cancer 91 2004 589 598
19. A. Mansouri, L.D. Ridgway, A.L. Korapati Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells J Biol Chem 278 2003 19245 19256
20. C. Hennequin, V. Favaudon Biological basis for chemo-radiotherapy interactions Eur J Cancer 38 2002 223 230
21. A.C. Begg Cisplatin and radiation interaction probabilities and therapeutic possibilities Int J Radiat Oncol Biol Phys 19 1990 1183 1189
22. W.K. Myint, C. Ng, G.P. Raaphorst Examining the non-homologous repair process following cisplatin and radiation treatments Int J Radiat Biol 78 2002 417 424
23. R. Gorodetsky, F. Levy-Agababa, X. Mou Combination of cisplatin and radiation in cell culture Effect of duration of exposure to drug and timing of irradiation Int J Cancer 75 1998 635 642
24. H. Bartelink, R.F. Kallman, D. Rapacchietta Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation Radiother Oncol 6 1986 61 74
25. H. Kanazawa, D. Rapacchietta, R.F. Kallman Schedule-dependent therapeutic gain from the combination of fractionated irradiation and cis- diamminedichloroplatinum (II) in C3H/Km mouse model systems Cancer Res 48 1988 3158 3164
26. L. Dewit Combined treatment of radiation and cisdiamminedichloroplatinum (II) A review of experimental and clinical data Int J Radiat Oncol Biol Phys 13 1987 403 426
27. E.C. Friedberg DNA damage and repair Nature 421 2003 436 440
28. J.A. Dolling, D.R. Boreham, D.L. Brown Cisplatin-modification of DNA repair and ionizing radiation lethality in yeast, Saccharomyces cerevisiae Mutat Res 433 1999 127 136
29. J. Haveman, N. Castro Kreder, H.M. Rodermond Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil Oncol Rep 12 2004 187 192
30. P. Frit, Y. Canitrot, C. Muller Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis-dichlorodiammineplatinum(II) Role of Ku autoantigen Mol Pharmacol 56 1999 141 146
31. J.J. Turchi, K.M. Henkels, Y. Zhou Cisplatin-DNA adducts inhibit translocation of the Ku subunits of DNA-PK Nucleic Acids Res 28 2000 4634 4641
32. E. Raymond, S.G. Chaney, A. Taamma Oxaliplatin A review of preclinical and clinical studies Ann Oncol 9 1998 1053 1071
33. S. Hector, W. Bolanowska-Higdon, J. Zdanowicz In vitro studies on the mechanisms of oxaliplatin resistance Cancer Chemother Pharmacol 48 2001 398 406
34. D. Pectasides, M. Pectasides, D. Farmakis Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer A phase II study Gynecol Oncol 95 2004 165 172
35. C.P. Saris, P.J. van de Vaart, R.C. Rietbroek In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells Carcinogenesis 17 1996 2763 2769
36. E.D. Scheeff, J.M. Briggs, S.B. Howell Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin Mol Pharmacol 56 1999 633 643
37. D. Fink, S. Nebel, S. Aebi The role of DNA mismatch repair in platinum drug resistance Cancer Res 56 1996 4881 4886
38. A. Vaisman, M. Varchenko, A. Umar The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance Correlation with replicative bypass of platinum-DNA adducts Cancer Res 58 1998 3579 3585
39. M. Espinosa, M. Martinez, J.L. Aguilar Oxaliplatin activity in head and neck cancer cell lines Cancer Chemother Pharmacol 55 2005 301 305
40. A. Cividalli, F. Ceciarelli, E. Livdi Radiosensitization by oxaliplatin in a mouse adenocarcinoma Influence of treatment schedule Int J Radiat Oncol Biol Phys 52 2002 1092 1098
41. B.D. Minsky Combined-modality therapy of rectal cancer with oxaliplatin-based regimens Clin Colorectal Cancer 4 suppl 1 2004 S29 S36
42. J.L. Grem 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development Invest New Drugs 18 2000 299 313
43. J.E. Byfield 5-Fluorouracil radiation sensitization-a brief review Invest New Drugs 7 1989 111 116
44. H.P. Schlemmer, M. Becker, P. Bachert Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy Cancer Res 59 1999 2363 2369
45. T.S. Lawrence, M.A. Davis, E.Y. Chang Lack of dependence of 5-fluorodeoxyuridine-mediated radiosensitization on cytotoxicity Radiat Res 143 1995 281 285
46. U. Nylen, E. Cekan, G.B. Jonasson Effects of 5-fluorouracil on cell cycle arrest and toxicity induced by X-irradiation in normal mammalian cells Cell Prolif 34 2001 85 98
47. L.L. Hughes, J. Luengas, T.A. Rich Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil Effects on cell survival, DNA repair, and cell recovery Int J Radiat Oncol Biol Phys 23 1992 983 991
48. C.E. Bruso, D.S. Shewach, T.S. Lawrence Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells Int J Radiat Oncol Biol Phys 19 1990 1411 1417
49. T.S. Lawrence, D.K. Heimburger, D.S. Shewach The effects of leucovorin and dipyridamole on fluoropyrimidine-induced radiosensitization Int J Radiat Oncol Biol Phys 20 1991 377 381
50. M.A. Davis, H.Y. Tang, J. Maybaum Dependence of fluorodeoxyuridine- mediated radiosensitization on S phase progression Int J Radiat Biol 67 1995 509 517
51. T.S. Lawrence, M.A. Davis, T.L. Loney Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation Cancer Res 56 1996 3203 3206
52. R.C. Zellars, J.D. Naida, M.A. Davis Effect of p53 overexpression on radiation sensitivity of human colon cancer cells Radiat Oncol Investig 5 1997 43 49
53. G. Nishimura, I. Terada, T. Kobayashi Thymidine phosphorylase and dihydropyrimidine dehydrogenase levels in primary colorectal cancer show a relationship to clinical effects of 5′-deoxy-5-fluorouridine as adjuvant chemotherapy Oncol Rep 9 2002 479 482
54. T. Hotta, K. Taniguchi, Y. Kobayashi Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue Oncol Rep 12 2004 539 541
55. N. Sawada, T. Ishikawa, F. Sekiguchi X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts Clin Cancer Res 5 1999 2948 2953
56. M. Barton-Burke Gemcitabine A pharmacologic and clinical overview Cancer Nurs 22 1999 176 183
57. W. Plunkett, P. Huang, Y.Z. Xu Gemcitabine metabolism, mechanisms of action, and self-potentiation Semin Oncol 22 1995 3 10
58. W. Plunkett, P. Huang, V. Gandhi Preclinical characteristics of gemcitabine Anticancer Drugs 6 suppl 6 1995 7 13
59. D.S. Shewach, T.S. Lawrence Gemcitabine and radiosensitization in human tumor cells Invest New Drugs 14 1996 257 263
60. D.S. Shewach, T.M. Hahn, E. Chang Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells Cancer Res 54 1994 3218 3223
61. T.S. Lawrence, E.Y. Chang, T.M. Hahn Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro- 2′-deoxycytidine (Gemcitabine) Clin Cancer Res 3 1997 777 782
62. J.W.G. van Putten, H.J.M. Groen, K. Smid End-joining deficiency and radiosensitization induced by gemcitabine Cancer Res 61 2001 1585 1591
63. F.M. Wachters, J.W. van Putten, J.G. Maring Selective targeting of homologous DNA recombination repair by gemcitabine Int J Radiat Oncol Biol Phys 57 2003 553 562
64. B.W. Robinson, M.M. Im, M. Ljungman Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells Cancer Res 63 2003 6935 6941
65. T.S. Lawrence, A.W. Blackstock, C. McGinn The mechanism of action of radiosensitization of conventional chemotherapeutic agents Semin Radiat Oncol 13 2003 13 21
66. T.S. Lawrence Radiation sensitizers and targeted therapies Oncology (Huntingt) 17 2003 23 28
67. B.B. Ma, R.G. Bristow, J. Kim Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents J Clin Oncol 21 2003 2760 2776
68. J. Mendelsohn, J. Baselga The EGF receptor family as targets for cancer therapy Oncogene 19 2000 6550 6565
69. B.G. Haffty Molecular and genetic markers in the local-regional management of breast cancer Semin Radiat Oncol 12 2002 329 340
70. K. Liang, K.K. Ang, L. Milas The epidermal growth factor receptor mediates radioresistance Int J Radiat Oncol Biol Phys 57 2003 246 254
71. S.M. Huang, J.M. Bock, P.M. Harari Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res 59 1999 1935 1940
72. A. Chakravarti, A. Dicker, M. Mehta The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas A review of preclinical and correlative clinical data Int J Radiat Oncol Biol Phys 58 2004 927 931
73. J.M. Gee, R.I. Nicholson Expanding the therapeutic repertoire of epidermal growth factor receptor blockade Radiosensitization Breast Cancer Res 5 2003 126 129
74. M. Baumann, M. Krause Targeting the epidermal growth factor receptor in radiotherapy Radiobiological mechanisms, preclinical and clinical results Radiother Oncol 72 2004 257 266
75. P.M. Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 2004 689 708
76. P.M. Harari, S.M. Huang Combining EGFR inhibitors with radiation or chemotherapy Will preclinical studies predict clinical results? Int J Radiat Oncol Biol Phys 58 2004 976 983
77. A. Wells EGF receptor Int J Biochem Cell Biol 31 1999 637 643
78. N. Magne, J.L. Fischel, A. Dubreuil ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity Rational basis for a new combination therapy with capecitabine Clin Cancer Res 9 2003 4735 4742